LONDON, ENGLAND, Imperial Innovations Group, a leading technology commercialisation and investment group, and SV Life Sciences have committed to invest 8 million pounds ($12.52 million) in a new start-up company TopiVert, which will focus on developing topical medicines for inflammatory diseases of the eye and gut.
Read More